ARMO Biosciences

Developing novel products to eradicate tumors

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel cytokine-based therapeutics that activate the immune system of cancer patients to recognize and eradicate tumors. The company’s pipeline includes product candidates aimed at treating a variety of cancers with significant unmet medical need in combination with standard of care and emerging immunotherapies. ARMO completed its IPO on NASDAQ in early 2018 and was acquired by Eli Lilly & Company in mid-2018.

IPO in 2018; Acquired by Eli Lilly in 2018
Year of Investment
Life Sciences
Redwood City, California